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patients with inoperable HCC (N=30) received single trans-
arterial chemoembolization (TACE) followed by volumetric-
modulated arc radiotherapy (VMAT)-based SBRT applying the 
van Herk margin recipe with mid-ventilation concept. Doses 
of SBRT were individualized according to normal tissue 
constraints. Tumor localization was performed by 4D CBCT 
using lipiodol as surrogate. Tumor responses were assessed by 
CT images using RECIST criteria every 3 months in the first 
year. In-field recurrence was defined as recurrence within 
the high-dose region (80% isodose volume). Overall survival, 
progression-free survival and local control rates were 
evaluated by the Kaplan-Meier method. Toxicities were 
graded according to CTCAE version 4.  
Results: Median follow-up time was 12 months (range: 4.2–
30.6 months). Patients’ characteristics were as follows: 
Median age (61 years, range: 28-87); Male/ female (n= 28/2); 
Child-Pugh class A/B (n= 28/2); ECOG 0-1/2 (n=21/9); BCLC 
stage A/B/C (n= 2/14/14); TNM stage I/II/III/IV 
(n=10/0/17/3); Solitary/ Multifocal (n=20/10); Portal vein 
thrombosis (n=8). Median size of tumor was 12.7cm (range: 
4.4-19.7cm) and Median GTV size was 937cc (range: 81-
3218cc). Median dose (2Gy equivalent, a/b=3) was 75Gy 
(range: 56-140Gy). Overall objective response rate was 67% 
(CR: n=1, PR: n=19). The 1-year in-field control, overall 
survival (OS) and progression-free survival (PFS) rate was 
86%, 65% and 42% respectively. Median survival not yet 
reached. Treatments were well tolerated. No grade 4-5 
toxicities were observed. Most common grade 3 toxicities 
were elevation of liver enzymes (n=6, 20%) and 
thrombocytopenia (n=1, 3%). No patient developed radiation-
induced liver disease (RILD).  
Conclusions: 4DCBCT guided SBRT using lipidiol as surrogate 
for tumor localization is feasible for inoperable HCC patients. 
It is safe, well tolerated and achieves high in-field control 
rate.  
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Purpose/Objective: Neo-adjuvant chemoradiotherapy (neo-
CRT) followed by surgery is currently the standard curative 
treatment for esophageal cancer. Both modalities may cause 
serious toxicity and morbidity. The aim of this study was to 
evaluate the incidence of pleural and pericardial effusion 
after neo-CRT followed by surgery and to investigate the 
impact on quality of life (QoL).  
Materials and Methods: Patients, that were included in a 
prospective trial to evaluate the impact of PET/CT for 
radiotherapy planning , underwent routine CT scanning 
during follow up in order to evaluate tumour recurrences. All 
these follow up CT's were blindly reviewed by a radiologist 
for signs of pleural and/or pericardial effusion. The degree of 
these toxicities was categorized as minor, moderate or 
severe. QoL questionnaires (EORTC QLQ-C30) were part of 
this follow up as well and were used to evaluate the impact 
of pleural and/or pericardial effusion . To investigate the 
relationship between pleural or pericardial effusion and the 
different domains of QoL a ANOVA was used. 
Results: Seventy-one patients were treated with neo-CRT and 
underwent routine CT scanning during follow up in absence of 
known recurrence and insufficient physical condition. The 
disease free survival (DFS) was 79%, 59% and 52% at 6, 12 and 
18 months after neo-CRT. At that time, 50, 42 and 35 
patients underwent follow up CT's. Pleural effusion occurred 
in 25 patients (50%) at 6 months and reduced over time; 33% 
at 12 months and 31% at 18 months. The degree was minor, 
moderate and severe in 11, 10 and 4 patients at 6 months. At 
18 months severe pleural effusion was still present in 3 
patients (9%). Pericardial effusion was seen in only 3 patients 
(6%) and completely reduced over time; 2.4% at 12 months 
and 0% at 18 months. Both pleural and pericardial effusion 
seemed of non-malignant origin, except for one patient with 
progressive malignant pleural effusion. Pleural effusion had a 
significant impact on physical functioning (p=0.001) and 
significantly enhanced dyspnoea (p=0.02). The mean score 
for physical functioning was 69 (SD: 26.3) in patients with 
pleural effusion vs. 82 (SD: 14.3) in absence of pleural 
effusion. Furthermore, pericardial effusion was significantly 
related to decreased global health status (39 vs. 75, p 
 
 
 
Conclusions: Pleural effusion is frequently observed after 
neo-CRT followed by surgical resection and improved over 
time and persisted up to 18 months pleural in 31% of the 
patients. Pericardial effusion is less common. Both pleural 
and pericardial effusions have a significant impact on QoL in 
terms of decreased physical functioning and increased 
dyspnoea.  
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